The following is a summary of the Aurora Cannabis Inc. (ACB) Q4 2024 Earnings Call Transcript:

Financial Performance:

• Net revenue for Aurora Cannabis increased by 21% on a trailing 12-month basis.

• Adjusted gross margin was reported at 49%.

• Positive adjusted EBITDA was achieved in each of the four fiscal quarters, marking the first time Aurora reported annual positive adjusted EBITDA.

• Cash balance ended the year at approximately $180 million.

Business Progress:

• Significant growth in the global medical cannabis business, accounting for 68% of total revenue and 90% of adjusted gross profit for the quarter.

• Acquired remaining 90% equity interest in MedReleaf Australia, strengthening position in Australia's medical cannabis market.

• Introduced new products including premium dried flower products and resin cartridges.

• Entered New Zealand and Switzerland markets, expanding global reach.

• Focused on medical cannabis, leveraging experience and EUGMP certified facilities to target internationally regulated markets.

Opportunities:

• Medical cannabis sector showing robust growth, with only about 1% of the Canadian adult population currently using medical cannabis, indicating significant potential for market expansion.

• Regulatory changes, like those in Germany, which recently descheduled cannabis, could increase patient access and market size, allowing Aurora to capitalize on these developments.

Risks:

• Decline in consumer cannabis revenue due to strategic shift towards higher-margin medical cannabis.

More details: Aurora Cannabis IR

Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.